United States Health

AbbVie (NYSE:ABBV) announced a multi-year collaboration with Iambic Therapeutics to apply artificial intelligence technologies to discover and develop small molecule therapies.

Helus Pharma (NASDAQ:HELP) presented four posters on its investigational oral deuterated psilocin analog HLP003 for major depressive disorder (MDD) at Psych Congress 2026 in New Orleans.

Alkermes (NASDAQ:ALKS) reported positive topline results from a phase 1 proof-of-concept study evaluating ALKS 7290, an investigational orexin 2 receptor agonist being developed for attention-deficit hyperactivity disorder (ADHD).

Precigen (NASDAQ:PGEN) received U.S. FDA platform technology designation for its AdenoVerse immunotherapeutic platform, which supports the company’s first commercial product, PAPZIMEOS.

Insmed (NASDAQ:INSM) received FDA Priority Review for its supplemental New Drug Application seeking full approval of ARIKAYCE (amikacin liposome inhalation suspension) for treating Mycobacterium avium complex (MAC) lung disease.

Merck (NYSE:MRK) announced that Japan’s Ministry of Health, Labour and Welfare approved KEYJECT (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous use across all indications approved for KEYTRUDA in Japan.

Novo Nordisk (NYSE:NVO) reported phase 3 topline results showing once-weekly CagriSema achieved weight loss and blood sugar reductions in adults with type 2 diabetes and obesity.

Cue Biopharma (NASDAQ:CUE) shares gained after the company reported positive results from a mid-stage study evaluating CUE-221 as a treatment for hives.

Novo Nordisk (NYSE:NVO) shares declined after the company presented its strategic ambitions for 2030 ahead of its Capital Markets Day, including long-term pipeline and obesity market targets.

GRAIL (NASDAQ:GRAL) shares rose sharply after U.S. Food and Drug Administration staff reviewers reported no major concerns regarding the safety and analytical performance of the company’s Galleri blood test designed to detect multiple cancers.

XORTX Therapeutics (NASDAQ:XRTX) announced plans to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration in the fourth quarter of 2026 for its XRx-026 gout program using the XORLO formulation of oxypurinol.

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for Enhertu (trastuzumab deruxtecan) in the adjuvant treatment of adults with resected HER2-positive breast cancer.